Objective: To assess the efficacy and toxicity of rhenium-186 HEDP in treating metastases. Patients: Twenty-six patients with bone pain from metastatic cancer were treated with 35 mCi of 186Re HEDP administered intravenously in the outpatient clinic. Methods: Patients were followed with pain diaries, records of medication, morbidity, sleep patterns, serial bone scans and a Karnofsky index. Twenty-five patients with complete records were evaluated. Patients were grouped according to the extent of bone metastases as seen in the bone scans. Results: Sixteen patients (64%) showed clinical responses of which 4 became completely pain-free. Pain relief typically began 10–20 days after 186Re HEDP was administered, while maximum benefit was normally achieved by 6 weeks. Relief of pain was maintained for 4–15 months (mean 6 months). No immediate adverse reactions were observed following the administration of 186Re HEDP. Only a mild transient fall in platelet levels was noted, which normalized by 6 weeks. Conclusion: 186RE HEDP appears as a safe, convenient and an effective palliative for pain secondary to bone metastases in cancer patients.

Keywords:
Rhenium-186 HEDP, Palliation of metastatic bone disease
This content is only available via PDF.
1999
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.